Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvotech teams up with China’s Changchun

Executive Summary

Biosimilars developer Alvotech has formedajoint venture with China’s Changchun High & New Technology Industries group (CCHN). The privately-owned Icelandic firm says the deal will enable it “to develop, manufacture and commercialise its biosimilars portfolio in China”. By aligning their “interests and strengths”, the partners plan to start buildingajointly-owned biologics manufacturing facility in Changchun, China, “as early as the first half of 2019”. Under the terms of the agreement, CCHN will put US$100 million into the joint venture, while Alvotech will contribute US$10 million of additional capital plus six marketing authorisations for monoclonal antibodies (mAbs) used for treating cancer and autoimmune diseases that it values at US$90 million CCHN’s general manager, An Jixiang, said the co-operation would “give full play to the advantages of both parties, and we are confident that we will haveafavourable position in China’s biosimilars market in future”.

You may also be interested in...

Alvotech Strikes $45m Deal With Yas Holding

Alvotech has struck an investment deal worth $45m that will give Yas Holding a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.

Alvotech Reels In Abdi Ibrahim For Access To Turkey

In a move to take its pipeline of biosimilar monoclonal antibodies global, Alvotech has struck a deal with Abdi Ibrahim that will give it localization advantages in Turkey.

Alvogen And Pfenex Broaden Teriparatide Collaboration

Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts